Evidence map›Paper›PMID 34308530›Full record

ArticleInterdisciplinary sciences, computational life sciences2022

Target-Based In Silico Screening for Phytoactive Compounds Targeting SARS-CoV-2.

Yong Zhao, Yu Tian, Chenling Pan, Aihua Liang, Wei Zhang, Yi Sheng

Open access · bronzeAbstract read
In one paragraph

Article in Interdisciplinary sciences, computational life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Yong Zhao *Beijing Computing Center, Beijing Academy of Science and Technology, 7 Fengxian Road, Beijing, 100094, China. yongzhao168@gmail.com.
Yu Tian *Department of Urology, Peking University Third Hospital, Beijing, 100191, China. tianyu@bjmu.edu.cn.
Chenling PanBeijing Computing Center, Beijing Academy of Science and Technology, 7 Fengxian Road, Beijing, 100094, China.
Aihua LiangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Wei ZhangThe Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON, Canada.
Yi ShengThe Department of Biology, York University, Life Sciences Building 327B, 4700 Keele Street, Toronto, ON, M3J 1P3, Canada. yisheng@yorku.ca.ORCID http://orcid.org/0000-0003-4083-7983
Beijing Computing Center · CNCanadian Institute for Advanced Research · CAChinese Academy of Medical Sciences & Peking Union Medical College · CNPeking University · CNYork University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19), resulting from infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can cause severe and fatal pneumonia along with other life-threatening complications. The COVID-19 pandemic has taken a heavy toll on the healthcare system globally and has hit the economy hard in all affected countries. As a result, there is an unmet medical need for both the prevention and treatment of COVID-19 infection. Several herbal remedies have claimed to show promising clinical results, but the mechanisms of action are not clear. We set out to identify the anti-viral natural products of these herbal remedies that presumably inhibit the life cycle of SARS-CoV-2. Particularly we chose four key SARS-CoV-2 viral enzymes as targets: Papain-like protease, Main protease, RNA dependent RNA polymerase, and 2'-O-ribose methyltransferase, which were subjected to an unbiased in silico screening against a small molecule library of 33,765 compounds originating from herbs and medicinal plants. The small molecules were then ranked based on their free energy of fitting into the "druggable" pockets on the surface of each target protein. We have analyzed the best "fit" molecules and annotated them according to their plant sources and pharmacokinetic properties. Here we present a list of potential anti-viral ingredients of herbal remedies targeting SARS-CoV-2 and explore the potential mechanisms of action of these compounds as a framework for further development of chemoprophylaxis agents against COVID-19.

Indexed as

COVID-19 Drug TreatmentPlants, MedicinalAntiviral AgentsHumansMolecular Docking SimulationPandemicsSARS-CoV-2Antiviral Agents2’-O-methyltransferaseCOVID-19In silico screeningMain proteaseNatural compoundsPapain-like proteaseRNA-dependent RNA polymerase

Identifiers

PMID34308530
PMCPMC8310681
OpenAlexW3186573005

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.